

Cholangiocarcinoma

Judy Wyatt

Dundee November 2010

Making sense of cholangiocarcinoma


Difficulties with diagnostic criteria

How many entities within cholangiocarcinoma?

Rapidly evolving



Cancer of Liver (C22) and Other Biliary Sites (C24) in Yorkshire Region 1976-2006




Intrahepatic cholangiocarcinoma

– encounters with the pathologist:

1. Liver needle biopsy diagnosis = adenocarcinoma
158 biopsies July 2005 – Jan 2009

Challenge for pathologist =
distinction primary v. metastatic
adenocarcinoma



2. Liver resection for cholangiocarcinoma:
40 specimens July 2005 – Jan 2009

Challenge for pathologist =
Accurately detect and record prognostic
features



1. Adenocarcinoma in liver biopsy – primary or metastatic?

Primary:

Cholangiocarcinoma

Metastatic adenocarcinoma:

colorectal

lung

pancreas



breast

stomach

gall bladder/bile duct

prostate

gynae



Immunohistochemistry - differential diagnosis of adenocarcinoma

Included in RCPATH Liver Datasets and Tissue Pathways documents

| % positivity for each marker | | | | | | | | |
|------------------------------|------|-------|----------|------|------|-----|----|-------------|
| Primary site | PS A | TTF 1 | GCDF P15 | CDX2 | CK20 | CK7 | ER | Meso-thelin |
| Breast | 0 | 0 | 49 | 0 | 0 | 87 | 79 | 4 |
| Colon | 0 | 0 | 6 | 86 | 76 | 3 | 1 | 7 |
| Lung | 0 | 97 | 3 | 1 | 1 | 92 | 6 | 36 |
| Ovary serous | 0 | 0 | 4 | 0 | 0 | 41 | 81 | 36 |
| Ovary mucinous | 7 | 0 | 14 | 14 | 14 | 57 | 50 | 36 |
| Pancreas | 0 | 4 | 1 | 1 | 2 | 91 | 0 | 49 |
| Stomach | 2 | 2 | 0 | 0 | 21 | 50 | 0 | 19 |
| Prostate | 100 | 8 | 4 | 4 | 0 | 0 | 8 | 0 |
| HCC | | 0 | 0 | 0 | 9 | 15 | 12 | 0 |
| Cholangio-carcinoma | | 0 | 0 | 22 | 49 | 55 | 0 | 44 |

| | CK7 | CK20 | ER | PR | TTF-1 | PSA |
|----------------|------|------|-----|------------------|-------|-----|
| Biliary | 81 | 33 | 4 | 29 | 0 | |
| Breast | 83 | 7 | 63 | 43 | 0 | 0 |
| Colon | 16 | 88 | 2 | 20 | 0 | 0 |
| Endometrium | 85 | 5 | 31 | 100 [†] | 0 | 3 |
| Kidney | 9 | 2 | 3 | 8 | 0* | 0* |
| Lung | 85 | 13 | 5 | 21 | 85 | 0 |
| Oesophagus | 50 | 29 | 0 | 100 [†] | 0 | 0 |
| Ovary | 73 | 23 | 53 | 32 | 1 | 2 |
| Pancreas | 95 | 32 | 0 | 2 | 1 | 0 |
| Prostate | 11 | 14 | 10 | 0* | 9 | 91 |
| Salivary gland | 100* | 50* | 25* | 25* | 0 | |
| Stomach | 49 | 37 | 0 | 5 | 1 | 3 |
| Urothelium | 74 | 72 | | | | 0 |

Ref: Dennis et al Clin Cancer Res 2005;11;3766-3772
and Frisman D. immunoquery.com

NICE guidelines: Diagnosis and management of metastatic malignant disease of unknown primary origin

Classification of cholangiocarcinoma: site of origin

- Peripheral intrahepatic
- Hilar
- Extrahepatic ducts


40% intrahepatic
7% hilar
53% extrahepatic

MacSween: Pathology of the liver:

15% intrahepatic
65% hilar
20% extrahepatic

Van Beers, HPB 2008;10;87-93

Evolutionary tree –
lumper or splitter



What is a cholangiocarcinoma?

- MacSween – Pathology of the liver:

‘features are very similar among tumours from any site, close resemblance to ductal adenocarcinoma of pancreas’


- WHO – classification of tumours of the Digestive System:

‘grossly classifiable into 3 types – mass forming, periductal infiltrating and intraductal papillary’

Liver Cancer Study Group of Japan (1997)

WHO: intrahepatic cholangiocarcinoma (2000)

- Mass forming – peripheral, large, sclerotic centre, cellular expansile margin
- Periductal infiltrating – arising from large ducts near hilum.
- Intraductal papillary – rare, good prognosis



Does this apply in UK?

2. Liver tumour resections, Leeds

Jun 05-Jan 09:

107 Hepatocellular carcinoma

40 CholangioCa →

Rare – limited numbers
for prognostic factors

7 Hepatoblastoma

↓

Most information in literature
is from Japan
– different epidemiology
- ? Can be translated to West

Many more resections for
metastatic colorectal cancer

Characteristics of 40 cholangiocarcinomas resected in Leeds June 2005-Jan 2009

| | Periductal infiltrating | Intrahepatic mass forming | P value |
|-------------------------|-------------------------|---------------------------|----------|
| Number | 21 | 18 | |
| Size (range) (mm) | 30 (13-50) | 87 (20-180) | <0.0002 |
| Margins +ve | 13 (8 duct margin) | 6 (0 duct margin) | <0.003 |
| Vascular invasion | 15 | 12 | 0.39 |
| Perineural infiltration | 21 | 7 | <0.00001 |
| Nodes +ve | 10 | 5 | 0.021 |

Plus 1 intraduct papillary adenocarcinoma

Proposal of progression model for ICC: Clinicopathological differences between hilar and peripheral types

Study of 87 tumours **<50mm** to investigate **early** patterns of spread.

| | Periductal infiltrating | intrahepatic Mass forming | P value |
|----------------------------|----------------------------|------------------------------|-------------------|
| number | 38 | 49 | |
| Size (mm)* | 30 +/- 11.6 | 33 +/-10.9 | 0.16 |
| Nodal metastases | 16 | 3 | 0.01 |
| Vascular invasion | 25 | 25 | 0.24 |
| Perineural invasion | 29 | 14 | <0.0001 |

Shinichi et al Am J Surg Pathol 2007:31:1059-1067.

Proposal of progression model for ICC: Clinicopathological differences between hilar and peripheral types

Study of 87 tumours **<50mm** to investigate **early** patterns of spread.

| | Periductal infiltrating | intrahepatic Mass forming | P value |
|----------------------------|----------------------------|------------------------------|-------------------|
| number | 38 | 49 | |
| Size (mm)* | 30 +/- 11.6 | 33 +/-10.9 | 0.16 |
| Nodal metastases | 16 | 3 | 0.01 |
| Vascular invasion | 25 | 25 | 0.24 |
| Perineural invasion | 29 | 14 | <0.0001 |
| Extrahepatic recurrence | 13 | 6 | <0.028 |
| Viral hepatitis | 4/35 | 21/45 | <0.002 |

Shinichi et al Am J Surg Pathol 2007:31:1059-1067.

Hilar Cholangiocarcinoma







Hilar Cholangiocarcinoma – Pathological Features



Desmoplastic / associated cholangitis / early lymphatic invasion
= can't detect its extent without histology

Characteristically:


1. Well differentiated
2. Perineural infiltration
3. Lymphatic invasion
4. Micrometastasis in nodes.



Hilar Cholangiocarcinoma - Klatskin tumour



CK19



CK19 x400

Cholangiocarcinoma, perihilar and extrahepatic ducts

Significant prognostic factors in 442 patients (75% perihilar), 1977-2005

| Variable | univariate | Relative risk | multivariate |
|--------------------------|------------|---------------|--------------|
| Differentiation | <0.0001 | 1.73 | 0.0002 |
| Lymphatic invasion | <0.0001 | | |
| Venous invasion | <0.0001 | 1.38 | 0.0098 |
| Perineural invasion | <0.0001 | 1.71 | 0.0067 |
| pT stage | <0.0001 | 1.45 | 0.0038 |
| Nodal metastasis | <0.0001 | 1.61 | 0.0005 |
| Resection margins | <0.0001 | 1.51 | 0.0034 |

Igami T et al. Nagoya. Ann Surg 2009;249;296-302

Cholangiocarcinoma: frequency of R0 resection v survival

| | Number of potentially curative resections | % R0 resections | 5 year survival of R0 resection |
|------------------------------|---|-----------------|---------------------------------|
| Leeds | 44 | 43% | 45% |
| Nagoya | 163 | 77% | 30% |
| Sloan Kettering ¹ | 80 | 78% | 29% |
| Tokyo ² | 65 | 48% | 51% |


1. Jarnagin WR *et al.* Ann Surg 2001;234:507-17

2. Kosuge T *et al.* Ann Surg 1999;230:663-674

Circumferential margin: transverse or longitudinal sections?


Serial transverse sections give better sampling of circumferential margin


Longitudinal sections give extent of tumour infiltration along duct wall*



* Sakamoto E et al. Ann Surg 1998;227:405-11


Hilar cholangiocarcinoma invading liver






Perihilar cholangiocarcinoma


- Desmoplastic,
- Well differentiated tubular
and poorly differentiated infiltrative
- Infiltrates liver along portal tracts
- No tumour mass – acquires infiltrative pattern early in development
- Cells spread out – go to nerves, nodes and resection margins



Portal plate,
extrahepatic biliary atresia



PSC



Ductal plate,
biliary embryogenesis

Bil IN – pre-malignant biliary epithelium, examples from patients with chronic biliary disease




Figure 3 Histological pictures of biliary lesions diagnosed as BilIN-2 by more than nine participants (hematoxylin and eosin; upper, $\times 100$; lower, $\times 400$).

Pre-cancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma


100 liver explants for PSC –
 28 prior Rx for CholangioCa
 2/72 had incidental CholangioCa
 10 more blocks from large ducts

| | Overall (100) | cholangioCa (30) | No cholangioCa (70) |
|-----------------------|---------------|------------------|---------------------|
| Dysplasia (any) | 50% | 25 (83%)* | 25 (36%) |
| Intestinal metaplasia | 26% | 13 (43%) | 13 (19%) |






* Dysplasia more extensive and more high grade

10% pancreatic metaplasia

Lewis JT *et al* Am J Surg Pathol 2010;34;27-34



A novel approach to biliary tract pathology based on similarities to pancreatic counterparts:
is the biliary tract an incomplete pancreas?




A novel approach to biliary tract pathology based on similarities to pancreatic counterparts: is the biliary tract an incomplete pancreas?


| Biliary tree | pancreas |
|---|---|
| IgG4 related sclerosing cholangitis | Lymphoplasmacytic sclerosing pancreatitis |
| Primary sclerosing cholangitis | Idiopathic duct-centric chronic pancreatitis |
| Conventional cholangiocarcinoma | Invasive duct carcinoma |
| Bil IN 1-3 | Pan IN 1-3 |
| Intraductal papillary neoplasm - IPNB | IPMN-P |
| Biliary cystic tumour with bile duct communication (cystic IPN) | IPMN-P with cystic change |
| Mucinous cystadenoma with ovarian-like stroma | Mucinous cystadenoma with ovarian-like stroma |

Intrahepatic, mass-forming cholangiocarcinoma





Pathology of peripheral intrahepatic cholangiocarcinoma with reference to tumorigenesis



| | Ductular CC (8) | Ductal CC (9) | Combined (7) |
|-----------------------------------|-----------------------------------|---------------|---------------------------------------|
| edge | Replacing, incorporates tracts | compressive | Ductular at edge, Ductal in centre |
| Central sclerosis | yes | yes | yes |
| CK7 and CK19+ve, HepPar1 -ve | yes | yes | yes |
| NCAM +ve | 11/15 | 0/16 | N/A |
| Advanced chronic liver disease | 62% | 22% | 29% |

Pathology of peripheral intrahepatic cholangiocarcinoma with reference to tumorigenesis

Relation to other tumours:

1. Cholangiolocellular carcinoma (Steiner, 1959)
2. Sclerosing hepatic carcinoma (Omata, 1981)
3. Combined HCC-CC
4. Hepatic stem cell malignancies in adults (Theise, 2003)

WHO 2010: 'combined HCC-CC with stem cell features'

Pathology of peripheral intrahepatic cholangiocarcinoma with reference to tumorigenesis

Relation to other tumours:

1. Cholangiolocellular carcinoma (Steiner, 1959)

–small cords and ductules

included combined HCC-CC

no consensus on diagnostic criteria

often multifocal


low association with chronic liver disease

Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin.


30 cases from Belgium and Japan, all with background chronic liver disease

>90% area cholangiolocellular

= small monotonous glands, abundant hyalinized stroma, lymphocytic infiltration



Komuta M,Roskams T. Hepatology 2008;47;1544-1556



‘When a HPC develops into cancer this can give rise to tumours with a whole spectrum of phenotypes with varying hepatocellular and cholangiocellular differentiation characteristics’

Komuta M,Roskams T. Hepatology 2008;47;1544-1556

Pathology of peripheral intrahepatic cholangiocarcinoma with reference to tumorigenesis

Relation to other tumours:

2. Sclerosing hepatic carcinoma (Omata, 1981)

intense fibrosis with embedded tubules
includes hepatocellular, ductal and mixed
69% hypercalcaemia

Omata M et al. Liver 1981;1;33-49

Pathology of peripheral intrahepatic cholangiocarcinoma with reference to tumorigenesis

Pathology of combined hepatocellular-cholangiocarcinoma


Relation to other tumours:

3. Combined HCC-CC

Very rare (<1%) – see HCC (makes bile)
and CC (makes mucin)

Or by immuno – HepPar1+ve, pCEA/CD10 canalicular
plus – mucin/muc protein by immuno
- not just CK7 , CK19

both components intimately mixed



Pathology of peripheral intrahepatic cholangiocarcinoma with reference to tumorigenesis


Relation to other tumours:

4. Hepatic stem cell malignancies in adults (Theise, 2003)

Four small tumours

contained undifferentiated cells with hepatic progenitor cells morphology and immunohistochemistry

merged with mature HCC and CC components




Mr FS 69M


treated haemochromatosis,

- Several early lesions on surveillance,
- Three lesions resected: 16mm 5mm 5mm





16mm lesion



5mm lesion




FS 16mm lesion x4




FS 5mm lesion x4


CK19+ve




FS 5mm lesion x20




CK19+ve




pCEA





HepPar1



Periductal infiltrating:



peripheral mass forming



Intraductal papillary – IPN – may be cystic

Cholangiocarcinoma

Hilar cholangiocarcinoma – right or left duct or common duct
' Klatskin tumour'

Intrahepatic cholangiocarcinoma

= intrahepatic malignancy with biliary epithelial differentiation

Distinguish – large ducts near hilum

- conventional cholangiocarcinoma with periductal infiltrating pattern


- intraductal papillary

small peripheral ducts/ductules

Liver Cancer Study Group of Japan (1997)


WHO: intrahepatic cholangiocarcinoma (2000)

- Mass forming – peripheral, large, sclerotic centre, cellular expansile margin



early

- Periductal infiltrating – arising from large ducts near hilum.



late

- Intraductal papillary – rare, good prognosis



Intrahepatic Cholangiocarcinoma

Large bile ducts with peribiliary glands –
periductal infiltrating, characteristics of hilar cholangiocarcinoma


Associated with – PSC, choledochal cysts, parasites

Peripheral – mass forming - small ducts
features resembling ductular reaction

often mixed phenotype
progenitor cell – biliary and hepatocellular characteristics

Associated with – cirrhosis, especially hep B and C

Intraductal papillary – spreads along lumen, includes cystic tumours that
lack mesenchymal stroma



Standards and Datasets for Reporting Cancers

**Dataset for liver resection specimens (including gall bladder) and liver biopsies for primary and metastatic
~~Carcinoma~~ (2nd edition)**

DRAFT: March 2010 31st October 2010

JIW, SGH, RDG



1st ed. 23 pages

2nd ed. 32 pages and counting

TNM 7 - recognises diversity in
cholangiocarcinoma

DATASET FOR LIVER RESECTION: COLORECTAL CANCER METASTASES Histopathology Report

Surname..... Fornames..... Date of birth..... Sex.....

Hospital..... Hospital number..... NHS number.....

Date of receipt..... Date of reporting..... Report number.....

Pathologist..... Surgeon.....

Gross description and core macroscopic items

Number of liver specimens received.....

Type of specimen: segmental resection non-anatomic (wedge) resection

Specimen weight (all specimens combined)

For segmental resections, specimen dimensions: antero-posterior.....mm, medio-lateral.....mm

Number of tumours present.....

Satellite lesions present yes no

List maximum diameters for up to 4 largest tumours

Distance from hepatic resection margin of nearest tumour

Liver capsule intact and smooth yes no

Invasion of adherent adjacent tissue yes no

Histology: core microscopic items

Tumour grade:

Well/moderately differentiated Poorly differentiated

For tumour closest to margin: Tumour cells present at margin yes

If no: margin >10mm or minimum distance to margin.....mm

Microscopic vascular invasion yes no

Histological features of tumour response to neoadjuvant chemotherapy

Background liver:

Normal steatosis chronic liver disease with fibrosis other.....

Signature of pathologist..... Date..... SNOMED codes.....

DATASET FOR LIVER RESECTION: CHOLANGIOCARCINOMA Histopathology Report

Surname..... Fornames..... Date of birth..... Sex.....

Hospital..... Hospital number..... NHS number.....

Date of receipt..... Date of reporting..... Report number.....

Pathologist..... Surgeon.....

Gross description and core macroscopic items

Type of specimen: segmental resection non-anatomic (wedge) resection list segments if known: Site/segment.....mm

Specimen weight.....g For segmental resections, specimen dimensions: antero-posterior.....mm, medio-lateral.....mm, super-inferior.....mm

Site of tumour: intrahepatic hilar extrahepatic

Maximum tumour size.....mm Distance from nearest hepatic resection margin.....mm

Distance from biliary duct resection margin.....mm

Hepatic metastases present yes no

Liver capsule intact and smooth yes no

Invasion of adherent adjacent tissue yes no

Lymph node(s) received.....

Word tumour grade: Well dif. Moder. Poorly

Predominant tumour grade: Well differentiated Moderately differentiated Poorly differentiated

Tumour cells present at hepatic margin yes

Tumour cells present at extrahepatic duct resection margin yes

Tumour cells present at circumferential margin yes

If no: margin >10mm or minimum distance to margin.....mm

Microscopic vascular invasion yes no

Peritoneal invasion yes no

Background liver disease: none primary at

Number of lymph nodes examined.....

Pathological Stage: Intrahepatic cholangiocarcinoma

PT0: no tumour identified PT1: no tumour without vascular invasion or nodal metastases

PT2: tumour with vascular invasion or nodal metastases

PT3: tumour with vascular invasion or nodal metastases and perforates

DATASET FOR LIVER RESECTION: HEPATOCELLULAR CARCINOMA Histopathology Report

Surname..... Fornames..... Date of birth..... Sex.....

Hospital..... Hospital number..... NHS number.....

Date of receipt..... Date of reporting..... Report number.....

Pathologist..... Surgeon.....

Gross description and core macroscopic items

Type of specimen: segmental resection list segments if known:..... non-anatomic (wedge) resection Site/segment of origin:.....mm

Specimen weight.....g For segmental resections, specimen dimensions: antero-posterior.....mm, medio-lateral.....mm, super-inferior.....mm

Number of tumours present..... List maximum tumour diameters:.....

Distance from nearest hepatic resection margin:.....mm

Macroscopic involvement of vessels yes no

Invasion of adherent adjacent organ yes no

Liver capsule intact and smooth yes no

Lymph node(s) received yes no

If yes, diameter of vessel involved.....mm If yes, which organ.....

Histology: core microscopic items

Tumour grade by worst area (Edmondson): grade 1 grade 2-3 grade 4

Tumour cells present at margin involved yes no

If no: margin >10mm or minimum distance to margin.....mm

Microscopic vascular invasion confirmed yes no

Microscopic vascular invasion yes no

Evidence of response to pre-operative treatment yes no

Background liver:

Fibrosis: none present act bridging bridging bridging with nodules complete cirrhosis

Aetiology: not known hepatitis B hepatitis C autoimmune hepatitis haemochromatosis alcohol NAFLD

Number with metastases:.....

PT0: no lymph node metastases PT1: lymph node metastases

PT2: tumour with vascular invasion or nodal metastases

PT3: tumour with vascular invasion or nodal metastases and perforates

PT4: tumour with vascular invasion or nodal metastases and perforates

Signature of pathologist..... Date..... SNOMED codes T...../M.....

Plus intrahepatic cholangiocarcinoma (and gall bladder)